Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.
Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Supragingival plaque was collected from five healthy participants and supragingival and subgingival plaque from five with gingivitis.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Narrative review · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not reported in the declared source.
Participants or experimental system
Not reported in the declared source.
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Not reported in the declared source.
Outcomes examined
The functional roles of the circadian clock of AVP neurons in the SCN were evaluated by genetically manipulating AVP neurons using the Cre-loxP system.
Key findings
These results suggest that cellular networks are crucial for coherent circadian rhythms in the SCN.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
The CRP concentrations in mouse sera were measured using a Mouse C-Reactive Protein ELISA Kit according to the protocol provided by the manufacturer.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The present study examines the response of neurons of PCG innervating uterine horn to axotomy caused by partial hysterectomy in the domestic pig animal model.
Study design
Not reported in the declared source.
Participants or experimental system
In remaining 5 animals only sham operation was performed.
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Preabsorption controls of antisera were done by preincubating the antibody with the specific immunogen (10 μg/ml) for 24 h under slow stirring at 4°C. Negative controls were performed by omitting all primary or secondary antibodies in the staining protocol.
Outcomes examined
Results were analyzed by Wilcoxon signed-rank test (Statistica 13.3, TIBCO Software Inc.).
Key findings
Our study showed that virtually all neurons of the porcine PCG innervating uterine horn are adrenergic and we did not confirm that PCG is the source of cholinergic fibers innervating uterine horn of the pig.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Using in vivo two-photon imaging and genetically encoded fluorescent indicators, we systematically investigate the GABA/glutamate/calcium dynamics of the primary visual cortex with cell-type specificity during isoflurane anaesthesia.
Study design
Here, we measured the dynamics of two major cortical neurotransmitters, gamma-aminobutyric acid (GABA) and glutamate, through in vivo two-photon imaging and genetically encoded neurotransmitter sensors in a cell type-specific manner in the primary visual (V1) cortex.
Participants or experimental system
The following mice (2-4 months old) were used in the experiments: VIP-ires-Cre, JAX Stock No. 010908; PV-ires-Cre, JAX Stock No. 008069; SOM-ires-Cre, JAX Stock No. 013044; and C57BL/6J, JAX Stock No. 000664.
Study scale
Not reported in the declared source.
Intervention or exposure
C57BL/6J mice were injected with the 1:1 virus mixture of AAV-CAMKII-cre with AAV-DIO-GCaMP6m, AAV-DIO-iGABASnFR, or AAV-DIO-iGluSnFR prepared on the day of injection.
Comparator
Not reported in the declared source.
Outcomes examined
To confirm the specific expression of the genetically encoded indicators GCaMP6m, iGABASnFR, and iGluSnFR in pyramidal, PV, SOM, and VIP neurons, we performed glutamate/PV/SOM/VIP immunohistochemistry.
Key findings
We found a general decrease in cortical GABA transmission during aLOC.
Limitations and uncertainty
Due to the limitation of spatiotemporal resolution, these results can reflect only the averaged glutamate level of the local neuronal population under stable anaesthesia and are far from sufficient to reveal the glutamate transients during the induction of unconsciousness.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not reported in the declared source.
Outcomes examined
The degree of erythema, skin thickening, and scaling on the affected area was quantified using the 4-point scale psoriasis area and severity index (PASI) (0=none; 1=slight; 2=moderate; 3=marked; 4=very marked).
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Narrative review · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not reported in the declared source.
Participants or experimental system
Not reported in the declared source.
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Not reported in the declared source.
Outcomes examined
Not reported in the declared source.
Key findings
HN and its analogs play a significant role in glucose homeostasis.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Study scale: The BAL fluid samples from LPS-exposed airways were pooled together (material from n = 10 healthy volunteers, total of 14 mL), cleared from debris by centrifugation (5,000 rpm for 15 min) and reconstituted in 0.1% TFA.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of this study was to detect citrullinated LL-37 in human bronchoalveolar lavage (BAL) fluid and to determine antibacterial and biophysical properties of citrullinated LL-37.
Study design
Not reported in the declared source.
Participants or experimental system
BAL fluid was obtained from healthy human volunteers after intra-bronchial exposure to lipopolysaccharide.
Study scale
The BAL fluid samples from LPS-exposed airways were pooled together (material from n = 10 healthy volunteers, total of 14 mL), cleared from debris by centrifugation (5,000 rpm for 15 min) and reconstituted in 0.1% TFA.
Intervention or exposure
Healthy human volunteers were exposed to LPS and after 24 h, BAL fluid samples were collected.
Comparator
In brief, healthy volunteers were exposed via bronchoscopy to vehicle, i.e., 10 mL of 0.9% PBS in one lung and to LPS (4 ng/kg) from Escherichia coli (E. coli) 0113:H10 (Rockville, MD, USA), diluted in PBS, in the other lung.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Thus it cannot be excluded that the initial screen revealed additional forms of citrullinated LL-37 that we could not distinguish with the LC-MS/MS analysis, due to analytical constraints.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
We have investigated the level of parameters related to stress in a group of post-menopausal female patients (age range 55-70 years) suffering by either objective or paradoxical insomnia, in particular we have measured 24-hours urinary cortisol, allostatic load index, Perceived Stress Scale (PSS) score, and, for the first time, mitokines (mitochondrial stress response molecules) such as FGF21, GDF15 and Humanin (HN).
Study design
They were divided in two groups (objective and paradoxical insomniacs, O-IN and P-IN) based on sleep efficiency (SE) values extrapolated from a one-week actigraphic monitoring.
Participants or experimental system
The patients were recruited consecutively as they accessed the laboratory of sleep disorders at the Bellaria Hospital, Bologna.
Study scale
Patients with SE < 85% were classified as O-IN (n = 14); those with SE > 85% were classified as P-IN (n = 24).
Intervention or exposure
Not reported in the declared source.
Comparator
We characterized a group of P-IN as compared with a group of O-IN for a number of parameters related to stress response, namely 24-h urinary cortisol, allostatic load, Perceived Stress Scale scores, and stress response molecules such as GDF15, FGF21 and HN.
Outcomes examined
Sleep efficiency was evaluated both by actigraphic monitoring and test batteries.
Key findings
Results show that the two groups are different as far as sleep efficiency score, as expected, but not for stress parameters, that in some cases resulted within the normality range, although quite close to the top threshold (such as cortisol) or much higher with respect to normality ranges (such as PSS).
Limitations and uncertainty
Therefore, even if we may consider variations due to different measurement conditions (such as collection in the 24 hours or at specific day time points) and possible confounders like gender and age, our data indicate the presence of an elevated amount of urinary cortisol in these insomnia patients, suggesting that they are experiencing a situation of stress.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Narrative review · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not reported in the declared source.
Participants or experimental system
Not reported in the declared source.
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Not reported in the declared source.
Outcomes examined
Not reported in the declared source.
Key findings
These results also suggest that increasing peripheral levels of oxytocin via intravenous administration does not appear to influence social cognition and neural activity via activation of peripheral oxytocin receptors, at least with a 1 IU intravenous dose.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Cytotoxicity was assessed using a Cell Counting Kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Inc.).
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of the study was to demonstrate the predictive value of the Baseline Prognostic Risk Score (BPRS) in moderate to severe TBI, in a sample of patients treated with neurotrophic factors.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Of the 142 patients enrolled in the CAPTAIN II study, 80 were in the active treatment group.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked